AOP Orphan Pharmaceuticals AG Release: Essential Thrombocythemia (ET) – Convincing Data of ANAHYDRET Study Now Published
3/18/2013 11:38:01 AM
More...
|
AOP Orphan Pharmaceuticals AG Reports Positive Phase II Data of Novel Mono-Pegylated Interferon Alpha 2b for Treatment of Polycythemia Vera (PV)
12/10/2012 1:07:37 PM
More...
|
Shield Signs Agreement for ST10-021 with AOP Orphan Pharmaceuticals AG
11/1/2010 1:15:42 PM
More...
|
AOP Orphan Pharmaceuticals AG and Lantibio Inc. Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
3/7/2007 10:16:31 AM
More...
|
Novelix Pharmaceuticals Inc. Announces Licensing of Cancer Compound to AOP Orphan Pharmaceuticals AG
2/26/2007 12:48:08 PM
More...
|
AOP Orphan Pharmaceuticals And Lantibio, Inc. Announce A Licensing And Commercialization Agreement For Moli1901 In Cystic Fibrosis
10/19/2005 5:11:32 PM
More...
|
AOP Orphan Pharmaceuticals AG Obtains Thromboreductin Registrations In Central Europe
10/19/2005 5:08:57 PM
More...
|